Methods
Balb/c mice were inoculated s.c. with 4T1 cells and thirteen days later, when tumors became palpable, randomly assigned to one of 4 treatment groups (n = 5 mice/group): control, RT alone, anti-CTLA-4 alone or RT+anti-CTLA-4. RT was given in 2 fractions of 12 Gy on days 13 and 14 post-tumor inoculation. Anti-CTLA-4 mAb (Clone 9H10) was given i.p. on days 15, 18 and 21. Tumors were harvested on day 22 for high throughput sequencing of TCRβ CDR3 regions performed using the ImmunoSEQ platform.
Results
Data indicate distinct non-overlapping effects of the combination treatment. CTLA-4 blockade increased clonality and significantly expanded the top 5 most frequent clonotypes. On the other hand, radiation augmented TIL numbers and broadened their repertoire by selective expansion of the top 6-20 clones. Importantly, analysis of Vβ/Jβ usage landscape showed that the combined treatment generated the most dramatic change from baseline with the expansion of several unique Vβ/Jβ combinations not seen in tumor treated with RT or CTLA-4 blockade alone.
Conclusions
Overall, data indicate that tumor rejection induced by RT +anti-CTLA-4 is associated with both quantitative and qualitative changes in the TIL repertoire. They also suggest that a broader repertoire of tumor-specific T cells may be critical for therapeutic success and is achieved by complementary effects of RT, which induces antigenic spread, and CTLA-4 blockade, which drives expansion of selected clones.
